Skip to main content

Peer Review reports

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Original Submission
29 Dec 2020 Submitted Original manuscript
17 Jan 2021 Reviewed Reviewer Report
15 Feb 2021 Reviewed Reviewer Report
3 Mar 2021 Author responded Author comments - Yuki Seo
11 Mar 2021 Author responded Author comments - Yuki Seo
Resubmission - Version 2
3 Mar 2021 Submitted Manuscript version 2
13 Mar 2021 Author responded Author comments - Yuki Seo
Resubmission - Version 3
13 Mar 2021 Submitted Manuscript version 3
23 Mar 2021 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
7 Apr 2021 Editorially accepted
20 Apr 2021 Article published 10.1186/s12876-021-01771-z

You can find further information about peer review here.

Back to article page